Theranostics Market by Product Type (Diagnostic Agents, Therapeutic Agents), Technology (Biomarker-Based Theranostics, Companion Diagnostics (CDx), Gene Therapy-Based Theranostics), Application Area, End-User - Global Forecast 2025-2032
Description
The Theranostics Market was valued at USD 2.93 billion in 2024 and is projected to grow to USD 3.32 billion in 2025, with a CAGR of 14.07%, reaching USD 8.40 billion by 2032.
Understanding the Foundations and Strategic Imperatives Driving the Transformative Evolution of Theranostics in Modern Healthcare Innovations
Theranostics represents a critical frontier in precision medicine, merging diagnostic and therapeutic processes to deliver targeted treatments that improve patient outcomes. This integrated model departs from traditional paradigms by employing diagnostic agents to identify molecular disease signatures and subsequently administering therapeutic agents designed to engage those exact biomarkers. As a result, clinicians can tailor interventions more accurately, reducing unnecessary side effects and elevating efficacy.
Over the past decade, advances in imaging modalities, radiopharmaceutical development, and molecular profiling have accelerated the adoption of theranostic approaches across a diverse range of clinical areas. From oncology to neurological disorders, the synergy between diagnostics and therapeutics has reshaped the development pipeline, prompted new regulatory pathways, and encouraged novel business collaborations between pharmaceutical, biotech, and medical device stakeholders.
This introduction sets the stage for a comprehensive exploration of transformative technology trends, regulatory evolutions, tariff impacts, and strategic imperatives that will determine the trajectory of the theranostics landscape. By understanding the foundational principles, current drivers, and emerging challenges, decision-makers can craft agile strategies that harness the full potential of this paradigm shift in modern healthcare.
Mapping the Pivotal Technological Advances and Emerging Trends Redefining the Competitive and Clinical Landscape of Theranostics Worldwide
The terrain of theranostics has been reshaped by a series of pivotal shifts that extend well beyond incremental innovation. Advances in molecular imaging have been paralleled by breakthroughs in nanotechnology-based drug delivery systems, enabling therapeutic payloads to be released directly at disease sites with unprecedented precision. At the same time, the integration of biomarker-based profiling has augmented companion diagnostic platforms, allowing for real-time treatment adjustments based on individual patient responses.
Artificial intelligence and machine learning have further accelerated this transformation by enabling the analysis of complex datasets and predictive modeling that guide both diagnostic accuracy and therapeutic efficacy. Regulatory frameworks are evolving to accommodate adaptive clinical trial designs and real-world evidence endpoints, which in turn incentivize faster market access and broadened indications.
Collaborative ecosystems have emerged, uniting pharmaceutical developers with imaging equipment manufacturers and digital health innovators to co-create integrated solutions. This convergence has not only streamlined research and development processes but has also opened new channels for value-based care models. As a result, theranostics is transitioning from a niche application in oncology to a cross-disciplinary strategy that spans autoimmune, cardiovascular, and neurological disorders, signaling a fundamental redefinition of how personalized medicine is delivered.
Evaluating the Cumulative Implications of the 2025 United States Tariff Revisions on Supply Chains and Cost Structures in the Theranostics Sphere
The implementation of revised tariff structures by the United States in 2025 introduces a significant variable into the economics of theranostics. Tariffs on imported radiopharmaceutical precursors, specialized imaging equipment components, and nanomaterial substrates have created upward pressure on production costs for both diagnostic and therapeutic agents. Manufacturers are now required to assess alternative sourcing strategies or absorb additional expenses, which may delay time to market or compress profit margins.
These changes have prompted a wave of strategic responses. Some organizations are accelerating efforts to localize component production, while others are exploring partnerships with domestic suppliers to mitigate exposure to border adjustments. Meanwhile, research institutions are reevaluating grant allocations for projects reliant on high-cost imported materials, potentially shifting focus toward locally sourced reagents and instrumentation.
Moreover, end-users such as imaging centers and specialty clinics face increased overheads, which could influence adoption rates of novel theranostic procedures. Payers and health systems may demand enhanced demonstration of clinical and economic value to justify higher reimbursement rates. Consequently, companies must enhance supply chain resilience, optimize cost structures, and reinforce the value proposition of integrated diagnostic-therapeutic solutions to maintain growth trajectories despite the tariff-induced headwinds.
Deciphering the Multifaceted Segmentation Framework That Illuminates Diverse Product, Technology, Application, and End-User Dynamics in Theranostics
Insightful segmentation of the theranostics market reveals nuanced drivers and opportunities across multiple dimensions. When examining product typology, there is a clear distinction between diagnostic agents that enable precise disease localization and therapeutic agents that leverage those diagnostic insights to deliver targeted interventions. Both categories operate in tandem, yet each follows distinct regulatory pathways and market adoption curves, necessitating bespoke development and commercialization strategies.
The underlying technologies powering these offerings encompass a broad spectrum. Biomarker-based theranostics harness molecular signatures for patient stratification, while companion diagnostics streamline treatment selection based on genetic or proteomic profiles. Gene therapy-based approaches modify cellular behavior at the DNA level, and molecular imaging provides dynamic visualization of treatment responses. Nanotechnology-based carriers enhance targeted delivery and reduce systemic toxicity, whereas radiopharmaceutical compounds enable both diagnostic scanning and radiotherapeutic effects. Targeted drug delivery platforms ensure that therapeutic payloads reach specific tissues, further optimizing risk-benefit profiles.
Applications span autoimmune disorders, cardiovascular diseases, infectious and inflammatory conditions, metabolic imbalances, and neurological pathologies. However, oncology remains the most mature vertical, with sub-segments in breast cancer, lung cancer, neuroendocrine tumors, prostate cancer, and thyroid cancer demonstrating robust R&D investment and clinical uptake. The ecosystem of end-users-from diagnostic imaging centers to hospitals and cancer care facilities, alongside research and academic institutes and specialty clinics-dictates treatment protocols and reimbursement negotiation dynamics, underscoring the importance of tailored engagement strategies for each stakeholder group.
Charting the Regional Trajectories Shaping Theranostics Adoption Across the Americas, Europe Middle East & Africa, and Asia-Pacific Domains
Regional dynamics play a critical role in shaping the pace and scale of theranostics adoption globally. In the Americas, leading markets benefit from established regulatory pathways and reimbursement frameworks, which facilitate the rapid introduction of innovative diagnostic and therapeutic combinations. Research institutions and healthcare networks in this region are heavily invested in clinical trials, driving early adoption of precision treatment protocols.
Across Europe, the Middle East, and Africa, heterogeneity in regulatory requirements and healthcare infrastructure presents both challenges and opportunities. Western Europe maintains rigorous approval processes and reimbursement policies, fostering collaboration between public health systems and private stakeholders. In emerging markets within the EMEA region, government-led initiatives aim to bolster access to advanced medical technologies, although constraints in funding and distribution networks may temper uptake in the near term.
The Asia-Pacific region is experiencing accelerated growth, propelled by robust government incentives, expanding healthcare infrastructure, and a growing emphasis on localized manufacturing. Markets such as China, Japan, and India are prioritizing precision medicine initiatives, leading to increased investment in molecular imaging centers and radiopharmaceutical production facilities. As a result, regional players are forging partnerships with global leaders to co-develop solutions that address unique demographic and epidemiological demands.
Profiling Leading Corporations Shaping the Competitive Landscape Through Innovative Collaborations, Pipeline Advancements, and Strategic Alliances
The competitive landscape of theranostics is driven by strategic investments from prominent life science and healthcare companies pursuing integrated diagnostic and therapeutic solutions. Major biopharmaceutical corporations are expanding their radiopharmaceutical pipelines, leveraging existing imaging expertise to enter adjacent therapeutic markets. Simultaneously, specialized biotech firms focus on novel biomarker discovery and targeted drug conjugates, often partnering with academic institutions to accelerate early-stage development.
Imaging equipment manufacturers are increasingly collaborating with pharmaceutical developers to co-create end-to-end platforms that blend hardware, software, and radiotracers. This convergence enables seamless workflow integration and positions these companies as full-service providers. Additionally, contract development and manufacturing organizations are scaling capabilities for radioisotope production and advanced formulation, supporting both established players and emerging entrants.
Strategic alliances and licensing agreements are prevalent, as organizations seek to de-risk R&D investment and strengthen market access. Several key players have formed joint ventures in regional markets to navigate complex regulatory landscapes and optimize distribution networks. These cooperative models not only expedite time to market but also generate shared expertise, driving incremental innovation across the value chain.
Actionable Strategic Roadmap Recommendations Empowering Industry Leaders to Accelerate Innovation, Optimize Operations, and Enhance Patient-Centric Value in Theranostics
Industry leaders aiming to capitalize on the theranostics opportunity must adopt a multifaceted strategic approach. First, investment in modular technology platforms that integrate diagnostics, imaging, and therapeutic delivery mechanisms will facilitate end-to-end solution offerings, enhancing differentiation and stakeholder retention. Second, forging partnerships with regional players and academic centers can accelerate clinical validation, enabling faster penetration of emerging markets while mitigating regulatory complexity.
Optimizing supply chain resilience through diversification of raw material sources and localized manufacturing will be essential to counter tariff volatility and geopolitical disruptions. Engaging proactively with payers and health authorities to demonstrate clinical and economic value will also be crucial; robust real-world evidence and health economics analyses should underpin reimbursement negotiations and market access strategies.
Finally, cultivating a talent pipeline with expertise in radiochemistry, molecular biology, and data analytics will drive sustained innovation. By embedding cross-functional teams that span R&D, regulatory affairs, and commercial operations, organizations can maintain agility, uphold compliance, and accelerate the translation of scientific breakthroughs into clinical practice.
Comprehensive Multi-Modal Research Methodology Integrating Primary Stakeholder Insights, Secondary Data Analyses, and Rigorous Validation Processes
This research employed a rigorous, multi-modal methodology to ensure accuracy, reliability, and relevance. Primary research included structured interviews with key stakeholders across pharmaceutical, biotechnology, medical device, and healthcare provider organizations. These interviews were designed to capture strategic imperatives, investment priorities, and on-the-ground perspectives regarding market adoption and clinical outcomes.
Secondary research involved systematic analysis of scientific literature, regulatory filings, patent databases, and industry publications. This process enabled comprehensive mapping of technological trends, competitive landscapes, and policy developments. Data triangulation techniques were applied to verify insights, cross-referencing quantitative data points with qualitative findings.
Validation workshops with independent experts provided additional scrutiny, refining assumptions and enhancing the robustness of segmentation frameworks. The final synthesis integrates these diverse inputs, delivering a cohesive narrative that aligns market intelligence with actionable recommendations.
Synthesis of Key Observations Reinforcing the Critical Role of Theranostics in Advancing Precision Medicine and Informing Strategic Decision Making
Theranostics stands at the nexus of diagnostic innovation and targeted therapy delivery, offering unprecedented potential to transform patient care across a spectrum of diseases. The convergence of advanced imaging, molecular profiling, and novel delivery platforms has given rise to a new paradigm in personalized medicine, one that promises improved clinical outcomes, streamlined workflows, and enhanced cost-effectiveness.
However, the landscape is complex, shaped by evolving regulatory frameworks, shifting trade policies, and heterogeneity in regional adoption curves. Success will hinge on the ability to navigate supply chain challenges, articulate clear value propositions to payers, and cultivate strategic partnerships that bridge technological and geographical gaps.
By synthesizing the foundational drivers, disruptive trends, segmentation dynamics, and strategic imperatives outlined in this summary, stakeholders can chart a path forward that harnesses the full promise of theranostics. The imperative now is to translate insight into action, fostering collaborations that accelerate innovation and ultimately deliver tailored treatments to patients in need.
Note: PDF & Excel + Online Access - 1 Year
Understanding the Foundations and Strategic Imperatives Driving the Transformative Evolution of Theranostics in Modern Healthcare Innovations
Theranostics represents a critical frontier in precision medicine, merging diagnostic and therapeutic processes to deliver targeted treatments that improve patient outcomes. This integrated model departs from traditional paradigms by employing diagnostic agents to identify molecular disease signatures and subsequently administering therapeutic agents designed to engage those exact biomarkers. As a result, clinicians can tailor interventions more accurately, reducing unnecessary side effects and elevating efficacy.
Over the past decade, advances in imaging modalities, radiopharmaceutical development, and molecular profiling have accelerated the adoption of theranostic approaches across a diverse range of clinical areas. From oncology to neurological disorders, the synergy between diagnostics and therapeutics has reshaped the development pipeline, prompted new regulatory pathways, and encouraged novel business collaborations between pharmaceutical, biotech, and medical device stakeholders.
This introduction sets the stage for a comprehensive exploration of transformative technology trends, regulatory evolutions, tariff impacts, and strategic imperatives that will determine the trajectory of the theranostics landscape. By understanding the foundational principles, current drivers, and emerging challenges, decision-makers can craft agile strategies that harness the full potential of this paradigm shift in modern healthcare.
Mapping the Pivotal Technological Advances and Emerging Trends Redefining the Competitive and Clinical Landscape of Theranostics Worldwide
The terrain of theranostics has been reshaped by a series of pivotal shifts that extend well beyond incremental innovation. Advances in molecular imaging have been paralleled by breakthroughs in nanotechnology-based drug delivery systems, enabling therapeutic payloads to be released directly at disease sites with unprecedented precision. At the same time, the integration of biomarker-based profiling has augmented companion diagnostic platforms, allowing for real-time treatment adjustments based on individual patient responses.
Artificial intelligence and machine learning have further accelerated this transformation by enabling the analysis of complex datasets and predictive modeling that guide both diagnostic accuracy and therapeutic efficacy. Regulatory frameworks are evolving to accommodate adaptive clinical trial designs and real-world evidence endpoints, which in turn incentivize faster market access and broadened indications.
Collaborative ecosystems have emerged, uniting pharmaceutical developers with imaging equipment manufacturers and digital health innovators to co-create integrated solutions. This convergence has not only streamlined research and development processes but has also opened new channels for value-based care models. As a result, theranostics is transitioning from a niche application in oncology to a cross-disciplinary strategy that spans autoimmune, cardiovascular, and neurological disorders, signaling a fundamental redefinition of how personalized medicine is delivered.
Evaluating the Cumulative Implications of the 2025 United States Tariff Revisions on Supply Chains and Cost Structures in the Theranostics Sphere
The implementation of revised tariff structures by the United States in 2025 introduces a significant variable into the economics of theranostics. Tariffs on imported radiopharmaceutical precursors, specialized imaging equipment components, and nanomaterial substrates have created upward pressure on production costs for both diagnostic and therapeutic agents. Manufacturers are now required to assess alternative sourcing strategies or absorb additional expenses, which may delay time to market or compress profit margins.
These changes have prompted a wave of strategic responses. Some organizations are accelerating efforts to localize component production, while others are exploring partnerships with domestic suppliers to mitigate exposure to border adjustments. Meanwhile, research institutions are reevaluating grant allocations for projects reliant on high-cost imported materials, potentially shifting focus toward locally sourced reagents and instrumentation.
Moreover, end-users such as imaging centers and specialty clinics face increased overheads, which could influence adoption rates of novel theranostic procedures. Payers and health systems may demand enhanced demonstration of clinical and economic value to justify higher reimbursement rates. Consequently, companies must enhance supply chain resilience, optimize cost structures, and reinforce the value proposition of integrated diagnostic-therapeutic solutions to maintain growth trajectories despite the tariff-induced headwinds.
Deciphering the Multifaceted Segmentation Framework That Illuminates Diverse Product, Technology, Application, and End-User Dynamics in Theranostics
Insightful segmentation of the theranostics market reveals nuanced drivers and opportunities across multiple dimensions. When examining product typology, there is a clear distinction between diagnostic agents that enable precise disease localization and therapeutic agents that leverage those diagnostic insights to deliver targeted interventions. Both categories operate in tandem, yet each follows distinct regulatory pathways and market adoption curves, necessitating bespoke development and commercialization strategies.
The underlying technologies powering these offerings encompass a broad spectrum. Biomarker-based theranostics harness molecular signatures for patient stratification, while companion diagnostics streamline treatment selection based on genetic or proteomic profiles. Gene therapy-based approaches modify cellular behavior at the DNA level, and molecular imaging provides dynamic visualization of treatment responses. Nanotechnology-based carriers enhance targeted delivery and reduce systemic toxicity, whereas radiopharmaceutical compounds enable both diagnostic scanning and radiotherapeutic effects. Targeted drug delivery platforms ensure that therapeutic payloads reach specific tissues, further optimizing risk-benefit profiles.
Applications span autoimmune disorders, cardiovascular diseases, infectious and inflammatory conditions, metabolic imbalances, and neurological pathologies. However, oncology remains the most mature vertical, with sub-segments in breast cancer, lung cancer, neuroendocrine tumors, prostate cancer, and thyroid cancer demonstrating robust R&D investment and clinical uptake. The ecosystem of end-users-from diagnostic imaging centers to hospitals and cancer care facilities, alongside research and academic institutes and specialty clinics-dictates treatment protocols and reimbursement negotiation dynamics, underscoring the importance of tailored engagement strategies for each stakeholder group.
Charting the Regional Trajectories Shaping Theranostics Adoption Across the Americas, Europe Middle East & Africa, and Asia-Pacific Domains
Regional dynamics play a critical role in shaping the pace and scale of theranostics adoption globally. In the Americas, leading markets benefit from established regulatory pathways and reimbursement frameworks, which facilitate the rapid introduction of innovative diagnostic and therapeutic combinations. Research institutions and healthcare networks in this region are heavily invested in clinical trials, driving early adoption of precision treatment protocols.
Across Europe, the Middle East, and Africa, heterogeneity in regulatory requirements and healthcare infrastructure presents both challenges and opportunities. Western Europe maintains rigorous approval processes and reimbursement policies, fostering collaboration between public health systems and private stakeholders. In emerging markets within the EMEA region, government-led initiatives aim to bolster access to advanced medical technologies, although constraints in funding and distribution networks may temper uptake in the near term.
The Asia-Pacific region is experiencing accelerated growth, propelled by robust government incentives, expanding healthcare infrastructure, and a growing emphasis on localized manufacturing. Markets such as China, Japan, and India are prioritizing precision medicine initiatives, leading to increased investment in molecular imaging centers and radiopharmaceutical production facilities. As a result, regional players are forging partnerships with global leaders to co-develop solutions that address unique demographic and epidemiological demands.
Profiling Leading Corporations Shaping the Competitive Landscape Through Innovative Collaborations, Pipeline Advancements, and Strategic Alliances
The competitive landscape of theranostics is driven by strategic investments from prominent life science and healthcare companies pursuing integrated diagnostic and therapeutic solutions. Major biopharmaceutical corporations are expanding their radiopharmaceutical pipelines, leveraging existing imaging expertise to enter adjacent therapeutic markets. Simultaneously, specialized biotech firms focus on novel biomarker discovery and targeted drug conjugates, often partnering with academic institutions to accelerate early-stage development.
Imaging equipment manufacturers are increasingly collaborating with pharmaceutical developers to co-create end-to-end platforms that blend hardware, software, and radiotracers. This convergence enables seamless workflow integration and positions these companies as full-service providers. Additionally, contract development and manufacturing organizations are scaling capabilities for radioisotope production and advanced formulation, supporting both established players and emerging entrants.
Strategic alliances and licensing agreements are prevalent, as organizations seek to de-risk R&D investment and strengthen market access. Several key players have formed joint ventures in regional markets to navigate complex regulatory landscapes and optimize distribution networks. These cooperative models not only expedite time to market but also generate shared expertise, driving incremental innovation across the value chain.
Actionable Strategic Roadmap Recommendations Empowering Industry Leaders to Accelerate Innovation, Optimize Operations, and Enhance Patient-Centric Value in Theranostics
Industry leaders aiming to capitalize on the theranostics opportunity must adopt a multifaceted strategic approach. First, investment in modular technology platforms that integrate diagnostics, imaging, and therapeutic delivery mechanisms will facilitate end-to-end solution offerings, enhancing differentiation and stakeholder retention. Second, forging partnerships with regional players and academic centers can accelerate clinical validation, enabling faster penetration of emerging markets while mitigating regulatory complexity.
Optimizing supply chain resilience through diversification of raw material sources and localized manufacturing will be essential to counter tariff volatility and geopolitical disruptions. Engaging proactively with payers and health authorities to demonstrate clinical and economic value will also be crucial; robust real-world evidence and health economics analyses should underpin reimbursement negotiations and market access strategies.
Finally, cultivating a talent pipeline with expertise in radiochemistry, molecular biology, and data analytics will drive sustained innovation. By embedding cross-functional teams that span R&D, regulatory affairs, and commercial operations, organizations can maintain agility, uphold compliance, and accelerate the translation of scientific breakthroughs into clinical practice.
Comprehensive Multi-Modal Research Methodology Integrating Primary Stakeholder Insights, Secondary Data Analyses, and Rigorous Validation Processes
This research employed a rigorous, multi-modal methodology to ensure accuracy, reliability, and relevance. Primary research included structured interviews with key stakeholders across pharmaceutical, biotechnology, medical device, and healthcare provider organizations. These interviews were designed to capture strategic imperatives, investment priorities, and on-the-ground perspectives regarding market adoption and clinical outcomes.
Secondary research involved systematic analysis of scientific literature, regulatory filings, patent databases, and industry publications. This process enabled comprehensive mapping of technological trends, competitive landscapes, and policy developments. Data triangulation techniques were applied to verify insights, cross-referencing quantitative data points with qualitative findings.
Validation workshops with independent experts provided additional scrutiny, refining assumptions and enhancing the robustness of segmentation frameworks. The final synthesis integrates these diverse inputs, delivering a cohesive narrative that aligns market intelligence with actionable recommendations.
Synthesis of Key Observations Reinforcing the Critical Role of Theranostics in Advancing Precision Medicine and Informing Strategic Decision Making
Theranostics stands at the nexus of diagnostic innovation and targeted therapy delivery, offering unprecedented potential to transform patient care across a spectrum of diseases. The convergence of advanced imaging, molecular profiling, and novel delivery platforms has given rise to a new paradigm in personalized medicine, one that promises improved clinical outcomes, streamlined workflows, and enhanced cost-effectiveness.
However, the landscape is complex, shaped by evolving regulatory frameworks, shifting trade policies, and heterogeneity in regional adoption curves. Success will hinge on the ability to navigate supply chain challenges, articulate clear value propositions to payers, and cultivate strategic partnerships that bridge technological and geographical gaps.
By synthesizing the foundational drivers, disruptive trends, segmentation dynamics, and strategic imperatives outlined in this summary, stakeholders can chart a path forward that harnesses the full promise of theranostics. The imperative now is to translate insight into action, fostering collaborations that accelerate innovation and ultimately deliver tailored treatments to patients in need.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
191 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Increasing adoption of personalized medicine driving theranostics demand
- 5.2. Growing integration of diagnostics and therapeutics in oncology treatment
- 5.3. Advancements in radiopharmaceuticals enhancing theranostic effectiveness
- 5.4. Rising prevalence of chronic diseases fueling precision treatment approaches
- 5.5. Technological innovations in molecular imaging and targeted therapy
- 5.6. Expanding applications of theranostics beyond oncology into cardiology and neurology
- 5.7. Strategic collaborations between pharma and diagnostic companies accelerating innovation
- 5.8. Regulatory support and streamlined approval processes boosting market growth
- 5.9. Growing patient demand for minimally invasive and targeted treatment solutions
- 5.10. Emergence of artificial intelligence in improving theranostic accuracy and outcomes
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Theranostics Market, by Product Type
- 8.1. Diagnostic Agents
- 8.2. Therapeutic Agents
- 9. Theranostics Market, by Technology
- 9.1. Biomarker-Based Theranostics
- 9.2. Companion Diagnostics (CDx)
- 9.3. Gene Therapy-Based Theranostics
- 9.4. Molecular Imaging
- 9.5. Nanotechnology-Based Theranostics
- 9.6. Radiopharmaceutical-Based Theranostics
- 9.7. Targeted Drug Delivery
- 10. Theranostics Market, by Application Area
- 10.1. Autoimmune Disorders
- 10.2. Cardiovascular Diseases
- 10.3. Infectious Diseases
- 10.4. Inflammatory Diseases
- 10.5. Metabolic Disorders
- 10.6. Neurological Disorders
- 10.7. Oncology
- 10.7.1. Breast Cancer
- 10.7.2. Lung Cancer
- 10.7.3. Neuroendocrine Tumors
- 10.7.4. Prostate Cancer
- 10.7.5. Thyroid Cancer
- 11. Theranostics Market, by End-User
- 11.1. Diagnostic Imaging Centers
- 11.2. Hospitals & Cancer Care Centers
- 11.3. Research & Academic Institutes
- 11.4. Specialty Clinics
- 12. Theranostics Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Theranostics Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Theranostics Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Actinium Pharmaceuticals, Inc.
- 15.3.2. Ariceum Therapeutics GmbH
- 15.3.3. Astellas Pharma Inc.
- 15.3.4. BAMF Health
- 15.3.5. Bayer AG
- 15.3.6. bioMérieux SA
- 15.3.7. Biosynth Ltd.
- 15.3.8. Cardinal Health, Inc.
- 15.3.9. Cerebral Therapeutics, Inc.
- 15.3.10. Clarity Pharmaceuticals
- 15.3.11. Curasight A/S
- 15.3.12. Curium Inc.
- 15.3.13. Evergreen Theragnostics, Inc.
- 15.3.14. GE HealthCare Technologies, Inc.
- 15.3.15. Hermes Medical Solutions AB
- 15.3.16. Icon Group
- 15.3.17. Indi Molecular, Inc.
- 15.3.18. Integrated Clinical Oncology Network Pty Ltd.
- 15.3.19. Radiopharm Theranostics Limited
- 15.3.20. Ratio Therapeutics
- 15.3.21. Siemens Healthineers AG
- 15.3.22. SOFIE Co.
- 15.3.23. Telix Pharmaceuticals Limited
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
